- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN Guidelines May Aid US Biosimilar Uptake, Cancer Experts Say
Payers view the National Comprehensive Cancer Network (NCCN) guidelines as a gold standard for making reimbursement decisions, according to a panel of experts who spoke recently about biosimilar uptake.
The National Comprehensive Cancer Network (NCCN) can be very helpful for biosimilar uptake because its guidelines allow for more breadth of use than FDA-approved indications, according to a panel of experts who spoke recently.
Payers view the NCCN guidelines as a gold standard for making reimbursement decisions. Thus, if biosimilars are listed in the guidelines, especially for indications that are off label, it could influence physician prescribing practices and lead to an uptake in biosimilar use, said Bhavesh Shah, RPh, BCOP, senior director of specialty and hematology/oncology pharmacy at Boston Medical Center Health System (BMCHS) of Massachusetts.
Tim Peterson, PharmD, BCOP, clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center in New York, New York, said biologics have been “a significant game changer” over previous, conventional chemotherapy agents. “But we’re now seeing this shift in the paradigm to biosimilars becoming available in different settings, and we’ll start to see more how those are adopted in clinical practice,” he said.
To read the full story, visit The Center for Biosimilars.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
